Found 6 matching trials
IFx-Hu2.0 Expanded Access Program N/A Expanded access requests for IFx-Hu2.0 may be considered for the treatment ...
Show More Location
Multiple Locations
Learn More & Join Trial
IFx-Hu2.0 for the Treatment of Patients With Skin Cancer PHASE1 One hundred patients will receive IFx-Hu2.0 on an outpatient basis at a sin...
Show More Location
Moore Clinical Research
Learn More & Join Trial
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor NaΓ―ve Participants With Advanced Or Metastatic Merkel Cell Carcinoma PHASE2 This Phase 2/3, multicenter, randomized, double-blind, placebo-controlled t...
Show More Location
USC Norris Comprehensive Cancer Center
Learn More & Join Trial
pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma EARLY_PHASE1 Six patients will receive IFx-Hu2.0 on an outpatient basis at a single time...
Show More Location
H. Lee Moffitt Cancer Center
Learn More & Join Trial
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) PHASE1 This Phase 1, multicenter, open-label trial will assess the safety and feas...
Show More Location
H. Lee Moffitt Cancer Center and Research Institute
Learn More & Join Trial
Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers PHASE1 In this clinical phase I, non-randomized, open-label, uncontrolled, interve...
Show More Location
USC Norris Comprehensive Cancer Center
Learn More & Join Trial